02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
20:40 , Sep 8, 2017 |  BC Week In Review  |  Company News

Aptevo regains rights to MOR209/ES414 from MorphoSys

Aptevo Therapeutics Inc. (NASDAQ:APVO) said it ended a 2014 deal with MorphoSys AG (Xetra:MOR; Pink:MPSYY) granting the German company worldwide rights to APVO414 (formerly MOR209/ES414). Aptevo plans to continue to develop the bispecific ADAPTIR molecule...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Emergent BioSolutions, Aptevo deal

Biodefense company Emergent completed its spin out of newco Aptevo, which will house Emergent’s oncology and hematology assets. Aptevo’s marketed products include hemophilia drug Ixinity trenonacog alfa. Its pipeline includes Emergent’s ADAPTIR platform, including bispecific...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Emergent BioSolutions cancer, hematology news

Emergent will spin out its biosciences business into a stand-alone, publicly traded company. The spinout will focus on oncology and hematology therapeutics and will receive $50-$70 million in cash from Emergent. The spinout will gain...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

MOR209/ES414: Phase I started

Emergent BioSolutions Inc . (NYSE:EBS), Rockville, Md.   MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany   Product: MOR209/ES414 (formerly ES414)   Business: Cancer   Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) ; CD3   Description:...
08:00 , Nov 10, 2014 |  BioCentury  |  Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
07:00 , Sep 22, 2014 |  BioCentury  |  Product Development

Glenmark's new cancer BEAT

While bispecific antibodies have been around for two decades, their success in cancer has been stymied by poor in vivo properties and complex manufacturing processes. Indian biotech Glenmark Pharmaceuticals Ltd. is making a play in...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, MorphoSys deal

MorphoSys partnered with Emergent to develop and commercialize ES414 . Emergent developed the bispecific ADAPTIR antibody targeting prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII ) and CD3. The compound -- to be renamed...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology....
01:47 , Aug 20, 2014 |  BC Extra  |  Company News

Emergent, MorphoSys to co-develop MOR209/ES414

MorphoSys AG (Xetra:MOR; Pink:MPSYF) partnered with Emergent BioSolutions Inc. (NYSE:EBS) to develop and commercialize ES414 , a bispecific ADAPTIR antibody targeting prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII ) and CD3. The compound...